FDA Bids Farewell to Old-School Cancer Drug Tablets
Published Date: 4/10/2026
Notice
Summary
GlaxoSmithKline has stopped selling Wellcovorin tablets and asked the FDA to withdraw its approval for these drugs as of April 10, 2026. This means Wellcovorin tablets (5 mg and 25 mg) can no longer be legally sold or shipped, but pharmacies can use up any leftover stock until it runs out or expires. If needed, GSK can apply again in the future to bring the drug back.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Wellcovorin approval withdrawn
The FDA withdrew approval of GlaxoSmithKline's New Drug Application (NDA 018342) for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg and EQ 25 mg, effective April 10, 2026. After that date, introducing or delivering these products into interstate commerce without an approved NDA violates the Federal Food, Drug, and Cosmetic Act.
Existing stock may still be dispensed
Any Wellcovorin (leucovorin calcium) tablets, EQ 5 mg and EQ 25 mg, that were in inventory on April 10, 2026 may continue to be dispensed until inventories are depleted, the products reach their expiration dates, or otherwise become violative—whichever comes first.
Withdrawal without prejudice to refiling
The FDA's withdrawal of approval is 'without prejudice' to refiling, meaning GlaxoSmithKline may apply in the future to seek approval again for Wellcovorin (NDA 018342).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-06910, Clean Air Act Operating Permit Program; Order on Petition for Objection to State Operating Permits for Bonanza Creek Energy Operating Company, LLC-Antelope CPF 13-21 Production Facility, State Antelope O-1 Central Production Facility, State North Platte 42-26 Central Production Facility and State Pronghorn 41-32 Central Production Facility
The EPA has decided not to block the air pollution permits for four Bonanza Creek Energy facilities in Colorado after reviewing a petition from an environmental group. This means the company can keep operating under the current permits, but the decision can be challenged in court by June 9, 2026. Local communities and the energy company are the main players affected by this ruling.
Next: 2026-06912, Tetrahydrofurfuryl Alcohol From the People's Republic of China: Final Results of the Expedited Fourth Sunset Review of the Antidumping Duty Order
The U.S. Department of Commerce decided to keep extra taxes on tetrahydrofurfuryl alcohol (THFA) imported from China because dropping them could let unfairly cheap products flood the market again. This move protects American producers and keeps the playing field fair. The decision took effect on April 10, 2026, so importers should be ready for these duties to continue.